OUR MODE 1-2-3 STRATEGY | HCL Technologies
Regeneron Announces Investor Conference Presentations. Regeneron News: Apr 23rd. New Dupixent® (dupilumab) Analyses at Two Upcoming Dermatology Congresses Reinforce Long-term Safety and Efficacy Profile in Patients with Atopic Dermatitis as Young as 6 Years. Now approved in two new patient populations. Now approved.
Get Price